<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981561</url>
  </required_header>
  <id_info>
    <org_study_id>3125-101-009</org_study_id>
    <nct_id>NCT04981561</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of GATE-251 in Normal Human Volunteers</brief_title>
  <official_title>A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AGN-241751 After Oral Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ronald M Burch MD PhD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gate Neurosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single ascending doses of GATE-251 in normal human&#xD;
      volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single ascending dose (SAD), double-blind placebo-controlled study in normal human&#xD;
      volunteers.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To evaluate the pharmacokinetics (PK) and eeg biomarker of target engagement of GATE-251&#xD;
      following increasing single doses of GATE-251.&#xD;
&#xD;
      GATE-251 or Placebo: Dose/Mode of Administration: Single dose; oral&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2016</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">December 21, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Triple blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>through study completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, maximum plasma concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, time to maximum plasma concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, area under the curve for plasma concentration</measure>
    <time_frame>72 hours</time_frame>
    <description>area under the curve, plasma calculated 0-infinity</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>100 microgram GATE-251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 100 microgram tablet, PO, Single Dose with 28 day follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg GATE-251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg GATE-251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 3 mg tablet, PO, Single Dose with 28 day follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg GATE-251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg GATE-251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 25 mg tablet, PO, Single Dose with 28 day follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg GATE-251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 50 mg tablet, PO, Single Dose with 28 day follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg GATE-251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 100 mg tablet, PO, Single Dose with 28 day follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg GATE-251 with CSF collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg GATE-251 with CSF collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet, PO, Single Dose with 28 day follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GATE-251</intervention_name>
    <description>Single dose of GATE-251</description>
    <arm_group_label>1 mg GATE-251</arm_group_label>
    <arm_group_label>1 mg GATE-251 with CSF collection</arm_group_label>
    <arm_group_label>10 mg GATE-251</arm_group_label>
    <arm_group_label>10 mg GATE-251 with CSF collection</arm_group_label>
    <arm_group_label>100 mg GATE-251</arm_group_label>
    <arm_group_label>100 microgram GATE-251</arm_group_label>
    <arm_group_label>25 mg GATE-251</arm_group_label>
    <arm_group_label>3 mg GATE-251</arm_group_label>
    <arm_group_label>50 mg GATE-251</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agree to effective method of birth control&#xD;
&#xD;
          -  If female, negative pregnancy test at screening and Day -1&#xD;
&#xD;
          -  Nonsmoking at least 2 years&#xD;
&#xD;
          -  BMI 18-30&#xD;
&#xD;
          -  Supine pulse rate 30-100&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to NMDA receptor drugs&#xD;
&#xD;
          -  clinically significant disease in any body system&#xD;
&#xD;
          -  QTcF &gt; 430 ms in males, &gt;450 ms in females&#xD;
&#xD;
          -  positive test for hepatitis B or C&#xD;
&#xD;
          -  abnormal liver function tests on Day -1&#xD;
&#xD;
          -  History of alcohol or other substance abuse during the previous 5 years&#xD;
&#xD;
          -  Positive drug screen at screening or Day -1&#xD;
&#xD;
          -  Taken any medication within the past 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M Burch, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gate Neurosciences, Inc</affiliation>
  </overall_official>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Gate Neurosciences, Inc</investigator_affiliation>
    <investigator_full_name>Ronald M Burch MD PhD</investigator_full_name>
    <investigator_title>Chief Medical Officer</investigator_title>
  </responsible_party>
  <keyword>NMDA receptor</keyword>
  <keyword>NMDA receptor positive allosteric modulator</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>biomarker</keyword>
  <keyword>eeg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

